63187-0379 Ondansetron

Product NDC:

63187-0379

Brand Name:

Ondansetron

Generic Name:

Ondansetron

Dosage Form Name:

Tablet, orally disintegrating

Administration Route:

Oral

Substances:

Name: Ondansetron

Strength: 4.0

Unit: mg/1

Packages:

Code: 63187-0379-03

Description: 3 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (63187-379-03)

Effective Date: Sept. 1, 2017

Discontinued:

Code: 63187-0379-05

Description: 5 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (63187-379-05)

Effective Date: Oct. 2, 2017

Discontinued:

Code: 63187-0379-10

Description: 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (63187-379-10)

Effective Date: Sept. 1, 2016

Discontinued:

Code: 63187-0379-12

Description: 12 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (63187-379-12)

Effective Date: Sept. 4, 2018

Discontinued:

Code: 63187-0379-15

Description: 15 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (63187-379-15)

Effective Date: Sept. 1, 2016

Discontinued:

Code: 63187-0379-20

Description: 20 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (63187-379-20)

Effective Date: Sept. 1, 2016

Discontinued:

Code: 63187-0379-30

Description: 30 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (63187-379-30)

Effective Date: Sept. 1, 2016

Discontinued:

Code: 63187-0379-06

Description: 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (63187-379-06)

Effective Date: March 30, 2023

Discontinued:

Code: 63187-0379-07

Description: 7 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (63187-379-07)

Effective Date: March 30, 2023

Discontinued:

SEER*Rx Category:

Ancillary Therapy

Major Class:

Antiemetic

Minor Class:

5HT3 Receptor Antagonist

Orphan Drug Designation:

Status:

In Use

Government Funding Lapse

CanMED: NDC

CanMED and the Oncology Toolbox

CanMED: NDC